GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice
Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure diagnoses in the United States, and the proportion continues to rise alongside the obesity epidemic. For decades, clinicians managing this phenotype had few effective pharmacologic tools — spironolactone and SGLT-2 inhibitors offered modest benefit in selected patients, but […]
